Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 8/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229475 | 1.00 | RXRB (0.36) | RXRBSLC2A1KCNH2MCHR1FGFR1 | |
| SCHEMBL23601960 | 0.86 | SLC6A2 (0.32) | — | |
| SCHEMBL23577160 | 0.86 | JAK2 (0.35) | SLC2A1KCNH2MCHR1KDM4E | |
| SCHEMBL29909278 | 0.83 | RXRB (0.37) | RXRBKDM4EALDH1A1HPGDHTT | |
| SCHEMBL23601648 | 0.78 | ALDH1A1 (0.38) | SLC2A1MCHR1KDM4EALDH1A1HPGD | |
| SCHEMBL23576730 | 0.77 | AOC3 (0.39) | KCNH2FGFR1KDR | |
| SCHEMBL23577533 | 0.74 | FGFR1 (0.39) | KCNH2FGFR1KDR | |
| SCHEMBL23577971 | 0.73 | PDE2A (0.39) | KDM4EALDH1A1HPGDHTT | |
| SCHEMBL29909436 | 0.73 | PDE2A (0.39) | KDM4EALDH1A1HPGDHTT | |
| SCHEMBL23601772 | 0.71 | MAT2A (0.45) | KDM4EALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | RXRB 1016/4885SLC2A1 3296/4885KCNH2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.